Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00217282 · ClinicalTrials.gov registry record · Phase 2
Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Mt. Sinai Medical Center, Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00217282 is a Phase 2 study that has completed, run by Mt. Sinai Medical Center, Miami. The registered enrollment target is 45 participants.
The verdict
NCT00217282, a Phase 2 study, has completed, sponsored by Mt. Sinai Medical Center, Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The combination of oxaliplatin and gemcitabine has proven activity in advanced non-small cell lung cancer (NSCLC). Due to its favorable toxicity profile, this combination is optimal for adding new agents. Bevacizumab is an anti-VEGF monoclonal antibody that has also shown favorable results in advanced NSCLC. This study will add bevacizumab to oxaliplatin and gemcitabine as first line treatment in patients with Stage IIIB and IV NSCLC.
Interventions
- DRUG oxaliplatin, gemcitabine, bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2004-06 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00217282
The ClinicalTrials.gov registry entry for NCT00217282 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mt. Sinai Medical Center, Miami, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which oxaliplatin, gemcitabine, bevacizumab is the first listed.
NCT00217282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00217282 about?
NCT00217282 is a clinical study titled "Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer". The combination of oxaliplatin and gemcitabine has proven activity in advanced non-small cell lung cancer (NSCLC). Due to its favorable toxicity profile, this combination is optimal for adding new agents. Bevacizumab is an anti-VEGF monoclonal antibody that has also shown favorable results in advanc...
What is the current status of trial NCT00217282?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2004-06. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00217282?
The interventions under investigation include: oxaliplatin, gemcitabine, bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00217282?
This trial is sponsored by Mt. Sinai Medical Center, Miami, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.